Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MGI Pharma and its partner Helsinn Healthcare have said that a patent term extension has been granted covering Aloxi injection in the US.
Subscribe to our email newsletter
This patent had originally been scheduled to expire in April 2010. Following this five year term extension, the patent will now expire in April 2015.
Aloxi is approved by the FDA for the prevention of acute nausea and vomiting associated with cancer chemotherapy. In addition, Aloxi is being developed for the prevention of post-operative nausea and vomiting (PONV), but is not approved for this indication.
According to the companies, Aloxi is the first and only 5-HT (3) receptor antagonist for the prevention of both acute and delayed CINV.
“Aloxi is a key brand franchise for MGI Pharma, and the five additional years of exclusivity granted by the US Patent and Trademark Office will ensure that we are able to maximize the value of this product to our shareholders,” said Lonnie Moulder, president and CEO of MGI Pharma.
“We look forward to working with our partner Helsinn to broaden the market potential of this product through the regulatory submissions planned for 2007.”